Deconstructing mTOR complexes in regulation of Glioblastoma Multiforme and its stem cells

Advances in Biological Regulation

Volumn 53, Issue 2, 2013, Pages 202-210

  Jhanwar Uniyal, Meena ^a   Jeevan, Dhruve ^a   Neil, Jayson ^a   Shannon, Craig ^a   Albert, Ladislau ^a   Murali, Raj ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIA;

EID: 84878612879     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2012.10.001     Document Type: Review

References (67)

1. Albert L., Karsy M., Murali R., Jhanwar-Uniyal M. Inhibition of mTOR activates the MAPK pathway in glioblastoma multiforme. Cancer Genomics Proteomics 2009, 6(5):255-261.
2. Bachmann R.A., Kim J.H., Wu A.L., Park I.H., Chen J. A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1. J Biol Chem 2006, 281:7357-7363.
3. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756-760.
4. Beier D., Hau P., Proescholdt M., Lohmeier A., Wischhusen J., Oefner P.J., et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007, 67(9):4010-4015.
5. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118(9):3065-3074.
6. Castilho R.M., Squarize C.H., Chodosh L.A., Williams B.O., Gutkind J.S. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell. 2009, 5(3):279-289.
7. Chang S.M., Wen P., Cloughesy T., Greenberg H., Schiff D., Conrad C., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005, 23(4):357-361.
8. Chappell W.H., Steelman L.S., Long J.M., Kempf R.C., Abrams S.L., Franklin R.A., et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011, 2(3):135-164.
9. Chen, Sarbassov The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2. J Biol Chem 2011, 286(46):40386-40394.
10. Choi J., Chen J., Schreiber S.L., Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996, 273(5272):239-242.
11. Cloughesy T., Yoshimoto K., Nghiemphu P., Brown K., Dang J., Zhu S., et al. Antitumor activity of rapamycin in a phase I trial for patients with reurentpten-deficient glioblastoma. PLoS Med 2008, 5:e8.
12. Dancey J., Curiel R., Purvis J. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin Oncol 2009, 36:S46-S58.
13. Demidenko Z.N., Zubova S.G., Bukreeva E.I., Pospelov V.A., Pospelova T.V., Blagosklonny M.V. Rapamycin decelerates cellular senescence. Cell Cycle 2009; Jun 15, 8(12):1888-1895.
14. Dorrello N.V., Peschiaroli A., Guardavaccaro D., Colburn N.H., Sherman N.E., Pagano M. Science 2006, 314:467-471.
15. Easley CAt, Ben-Yehudah A., Redinger C.J., Oliver S.L., Varum S.T., Eisinger V.M., et al. mTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells. Cell Reprogram 2010, 12:263-273.
16. Galanis E., Buckner J.C., Maurer M.J., Kreisberg J.I., Ballman K., Boni J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005, 23(23):5294-5304.
17. Galli R., Binda E., Orfanelli U., Cipelletti B., Gritti A., De Vitis S., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004, 64(19):7011-7021.
18. Gingras A.C., Raught B., Gygi S.P., Niedzwiecka A., Miron M., Burley S.K., et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001, 15(21):2852-2864.
19. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell. 2007, 12(1):9-22.
20. Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci Signal 2009, 2(67):e24.
21. Gulati N., Karsy M., Albert L., Murali R., Jhanwar-Uniyal M. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Int J Oncol 2009, 35(4):731-740.
22. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004, 166:213-223.
23. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009 Jul 16, 460(7253):392-395. Epub 2009 Jul 8.
24. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18(16):1926-1945.
25. Heitman J., Movva N.R., Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991, 253:905-909.
26. Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 2003, 100(25):15178-15183.
27. Holland E.C. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001, 2(2):120-129.
28. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002 Oct, 22(20):7004-7014.
29. Ignatova T.N., Kukekov V.G., Laywell E.D., Suslov O.N., Vrionis F.D., Steindler D.A. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002 Sep, 39(3):193-206.
30. Jacinto E., Loewith R., Schmidt A., Lin S., Rüegg M.A., Hall A., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004, 6(11):1122-1128. Epub 2004 Oct 3.
31. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006 Oct 6, 127(1):125-137. Epub 2006 Sep 7.
32. Jhanwar-Uniyal M., Albert L., McKenna E., Karsy M., Rajdev P., Braun A., et al. Deciphering the signaling pathways of cancer stem cells of glioblastoma multiforme: role of Akt/mTOR and MAPK pathways. Adv Enzym Regul 2011, 51(1):164-170.
33. Kelly J.J., Stechishin O., Chojnacki A., Lun X., Sun B., Senger D.L., et al. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells 2009, 27(8):1722-1733.
34. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110(2):163-175.
35. Korotchkina L.G., Leontieva O.V., Bukreeva E.I., Demidenko Z.N., Gudkov A.V., Blagosklonny M.V. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2010, 2:344-352.
36. Kubica N., Crispino J.L., Gallagher J.W., Kimball S.R., Jefferson L.S. Activation of the mammalian target of rapamycin complex 1 is both necessary and sufficient to stimulate eukaryotic initiation factor 2Bvarepsilon mRNA translation and protein synthesis. Int J Biochem Cell Biol 2008, 40(11):2522-2533. Epub 2008 May 15.
37. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367(6464):645-648.
38. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
39. Liu Q., Nguyen D.H., Dong Q., Shitaku P., Chung K., Liu O.Y., et al. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol 2009, 94(1):1-19.
40. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002 Sep, 10(3):457-468.
41. Martelli A.M., Tazzari P.L., Evangelisti C., Chiarini F., Blalock W.L., Billi A.M., et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 2007, 14(19):2009-2023.
42. Matsumoto K., Arao T., Tanaka K., Kaneda H., Kudo K., Fujita Y, et al. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 2009, 69:7160-7164.
43. McCord A.M., Jamal M., Shankavaram U.T., Lang F.F., Camphausen K., Tofilon P.J. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 2009, 7:489-497.
44. Ohgaki H., Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009, 100(12):2235-2241.
45. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006, 9(3):157-173.
46. Platet N., Liu S.Y., Atifi M.E., Oliver L., Vallette F.M., Berger F., et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007, 258:286-290.
47. Prestegarden L., Svendsen A., Wang J., Sleire L., Skaftnesmo K.O., Bjerkvig R., et al. Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res 2010, 70(11):4274-4279.
48. Reardon D., Quinn J., Vredenburgh J., Gururangan S., Friedman A.H., Desjardins A., et al. Phase I trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006, 12:860-868.
49. Reardon D., Desjardins A., Vredenburgh J., Gururangan S., Friedman A.H., Herndon J.E., et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 2010, 96:219-230.
50. Reiling J.H., Sabatini D.M. Stress and mTORture signaling. Oncogene 2006, 25:6373-6383.
51. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414(6859):105-111.
52. Riemenschneider M.J., Betensky R.A., Pasedag S.M., Louis D.N. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 2006, 66:5618-5623.
53. Rosner M., Hengstschläger M. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet 2008, 17(19):2934-2948.
54. Russell R.C., Fang C., Guan K.L. An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development 2011, 138:3343-3356.
55. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006, 6:729-734.
56. Salomoni P., Pandolfi P.P. The role of PML in tumor suppression. Cell 2002, 108:165-170.
57. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004 Jul 27, 14(14):1296-1302.
58. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307(5712):1098-1101.
59. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003 Sep 15, 63(18):5821-5828.
60. Singh S.K., Clarke I.D., Hide T., Dirks P.B. Cancer stem cells in nervous system tumors. Oncogene 2004, 23(43):7267-7273.
61. Soeda A., Park M., Lee D., Mintz A., Androutsellis-Theotokis A., McKay R.D., et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009, 28(45):3949-3959.
62. Stupp R., Hegi M. Targeting brain-tumor stem cells. Nat Biotechnol 2007, 25:193-194.
63. Tamburini J., Chapuis N., Bardet V., Park S., Sujobert P., Willems L., et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008, 111:379-382.
64. Tee A.R., Blenis J., Proud C.G. Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1. elevated p70 S6 kinase activation induces differentiation of human embryonic stem cells (hESCs). FEBS Lett 2005, 579:4763-4768.
65. Volarevic S., Thomas G. Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 2001, 65:101-127.
66. You H., Ding W., Rountree C.B. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010, 51:1635-1644.
67. Zhou J., Su P., Wang L., Chen J., Zimmermann M., Genbacev O., et al. mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells. Proc Natl Acad Sci U S A 2009, 106(19):7840-7845.